Mechanistic evidence from peer-reviewed studies implicates GPR65 as a modulator of cancer progression via the promotion of tumour cell adaptation to acidosis, conferring resultant survival benefits and immune evasion [64,65]. Here, GPR65 is linked to neoplasm.